How to appeal a Highmark treatment-resistant depression — rtms, spravato, ect denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for treatment-resistant depression — rtms, spravato, ect

Cited policy: BCBS Medical Policy: SAINT / Accelerated TMS for Treatment-Resistant Depression

TRD diagnosis (F32.x / F33.x) — failure of >=2 adequate antidepressant trials. Magnus Medical SAINT Neuromodulation System (FDA-cleared Sep 2022). Protocol: 10 iTBS sessions/day x 5 days, fMRI-guided sgACC functional-connectivity targeting. Single course; reauth for repeat course requires response documentation.

How Highmark denies treatment-resistant depression — rtms, spravato, ect — and how to counter it

Where Highmark pushes back: 1) SAINT 'experimental / investigational'; 2) Accelerated rTMS not covered; 3) fMRI-targeting not standard.

Counter-arguments that hold up: SAINT / SNT received FDA 510(k) clearance Sep 6, 2022 to Magnus Medical (K222909) — NOT investigational. Cole AJP 2022 pivotal — 79% remission in TRD with single 5-day course. Cole et al 2024 SNT replication. Accelerated iTBS protocol cleared by FDA — coverage cannot be denied as 'experimental' for cleared device. fMRI-guided sgACC targeting is part of cleared device's labeled protocol.

What Highmark typically denies for treatment-resistant depression — rtms, spravato, ect

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For treatment-resistant depression — rtms, spravato, ect, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the treatment-resistant depression — rtms, spravato, ect treatments most often flagged for prior auth, step therapy, or medical necessity review:

• NeuroStar rTMS (10 Hz)
• Brainsway Deep TMS
• Magstim Horizon rTMS
• MagVenture rTMS
• iTBS (theta-burst)
• SAINT / SNT accelerated iTBS

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.